Category Archives: Cf

TORONTO and NEW YORK, Feb. 15, 2022 /PRNewswire/ -- CF Acquisition Corp. VI (Nasdaq: CFVI), a special purpose acquisition company sponsored by Cantor Fitzgerald, and Rumble Inc. ("Rumble"), the neutral video platform, announced today that CFVI has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement") in connection with the proposed business combination with Rumble.

CFVI and Rumble announced on December 1, 2021, that they entered into a definitive business combination agreement. Assuming no redemptions by CFVI stockholders and prior to giving effect to transaction expenses, the transaction will provide approximately $400 million of proceeds at close, including $100 million of proceeds from a PIPE financing and $300 million of cash held in the trust account of CFVI. The proceeds will be used to attract new content creators to the Rumble and Locals platforms, continue to build out Rumble's independent infrastructure, expand Rumble's teams, begin robust marketing of the platform and services, make future acquisitions, and for other general corporate purposes.

The transaction has been unanimously approved by the board of directors of CFVI, as well as the board of directors of Rumble, and is expected to close during the second quarter of 2022, subject to the Registration Statement being declared effective by the SEC, approval by CFVI and Rumble shareholders, and other customary closing conditions. Rumble's strategy is currently focused on continuing its explosive growth in users and user engagement, as well as building the tools that will enable future monetization of this consumption.

About Rumble

Rumble is a high growth neutral video distribution platform. Rumble has created rails and independent infrastructure that are designed to be immune to cancel culture. Rumble's mission is to restore the internet to its roots based on freedom of expression and creativity.

Story continues

About CF Acquisition Corp. VI

CFVI is a blank check company led by Chairman and Chief Executive Officer Howard W. Lutnick and sponsored by Cantor Fitzgerald.

About Cantor Fitzgerald

Cantor Fitzgerald, with over 12,000 employees, is a leading global financial services group at the forefront of financial and technological innovation and has been a proven and resilient leader for 77 years. Cantor Fitzgerald & Co. is a preeminent investment bank serving more than 5,000 institutional clients around the world, recognized for its strengths in fixed income and equity capital markets, investment banking, SPAC underwriting and PIPE placements, prime brokerage, and commercial real estate on its global distribution platform. Cantor Fitzgerald & Co. is one of 24 primary dealers transacting business with the Federal Reserve Bank of New York. For more information, please visit: http://www.cantor.com.

Important Information and Where to Find It

The proposed transactions will be submitted to CFVI's stockholders for their consideration and approval at a special meeting of stockholders. In connection with the proposed transactions, CFVI has filed the Registration Statement, which included a preliminary proxy statement / prospectus in connection with CFVI's solicitation of proxies for the vote by CFVI's stockholders in connection with the proposed transactions and other matters as described in such Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Rumble's shareholders in connection with the completion of the proposed transactions. After the Registration Statement has been declared effective, CFVI will mail a definitive proxy statement / prospectus and other relevant documents to its stockholders as of the record date established for voting on the proposed transactions. Investors and security holders of CFVI are advised to read the preliminary proxy statement and any amendments thereto, and, when available, the definitive proxy statement / prospectus, in connection with CFVI's solicitation of proxies for its special meeting of stockholders to be held to approve the proposed transactions because the proxy statement / prospectus will contain important information about the proposed transaction and the parties to the proposed transactions. Investors and security holders will be able to obtain free copies of the Registration Statement, including the proxy statement / prospectus and all other relevant documents filed or that will be filed with the SEC by CFVI through the website maintained by the SEC at http://www.sec.gov. The documents filed by CFVI with the SEC also may be obtained free of charge upon written request to CFVI at 110 East 59th Street, New York, NY 10022.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS PRESS RELEASE, PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PRESS RELEASE. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Participants in the Solicitation

CFVI and Rumble and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from CFVI's stockholders in connection with the proposed transactions. CFVI's stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and executive officers of CFVI in the Registration Statement. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies from CFVI's stockholders in connection with the proposed business combination is set forth in the Registration Statement.

No Offer or Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of CFVI or Rumble, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed transaction between CFVI and Rumble. Such forward-looking statements include, but are not limited to, statements regarding the closing of the transaction and CFVI's, Rumble's, or their respective management teams' expectations, hopes, beliefs, intentions or strategies regarding the future. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intends", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to assumptions, risks and uncertainties. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of CFVI and Rumble. Many factors could cause actual future events to differ from the forward looking-statements in this press release, including but not limited, to (i) the risk that the transaction may not be completed in a timely manner or at all, (ii) the failure to satisfy the conditions to the consummation of the transaction, (iii) the inability to complete the PIPE offering, (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement , (v) the outcome of any legal proceedings that may be instituted against Rumble and/or CFVI related to the business combination agreement, (vi) the ability to maintain the listing of CFVI stock on Nasdaq (or, if applicable, to list and maintain the listing of the combined entity on the NYSE), (vii) costs related to the transactions and the failure to realize anticipated benefits of the transactions, (viii) the effect of the announcement or pendency of the transaction on Rumble's business relationships, operating results, performance and business generally, (ix) changes in the combined capital structure of Rumble and CFVI following the transactions, (x) changes in laws and regulations affecting Rumble's business, (xi) risks related to Rumble's potential inability to achieve or maintain profitability and generate cash, (xii) the enforceability of Rumble's intellectual property, including its patents and the potential infringement on the intellectual property rights of others, (xiii) the potential for and impact of cyber related attacks, events or issues effecting Rumble, its business and operations, and (xiv) other risks and uncertainties indicated from time to time in the filings of CFVI, including the definitive Registration Statement that CFVI will file, which will include a proxy statement/prospectus related to the potential business combination. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Rumble and CFVI assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Rumble nor CFVI gives any assurance that either Rumble or CFVI will achieve its expectations.

Cision

View original content:https://www.prnewswire.com/news-releases/cf-acquisition-corp-vi-and-rumble-announce-filing-of-a-registration-statement-in-connection-with-their-proposed-business-combination-301482200.html

SOURCE Rumble and CFVI

Here is the original post:

CF Acquisition Corp. VI and Rumble Announce Filing of a Registration Statement in Connection with their Proposed Business Combination - Yahoo Finance

Thanks to the MLB owner-imposed lockout, the Texas Rangers will not report to spring training on Feb. 14, as had been the original schedule. Nevertheless, we begin preparation for the start of camp, whenever that may be. Our daily, position-by-position look around the Rangers roster as it sits with construction stalled:

Likely starter: Adolis Garca

On the bench: Eli White, Leodys Taveras

Surveying the market: The Rangers could use an extra body as a backup in case White isnt physically ready to start the season and in case Taveras is still not ready to hit in the big leagues. Unless the Rangers went all in with Michael Conforto, it would probably be a minor league contract type of guy. Old friend Delino DeShields is out there. So are the likes of Jake Marisnick, Juan Lagares and Mike Tauchman, who spent part of 2021 in San Francisco with new Rangers bench coach/offensive coordinator Donnie Ecker.

What happened in 2021: Not on the opening day roster, Garca (added a week into the season) was the best thing to happen to the Rangers in the first half. He ended up a rookie All-Star thanks to 22 homers, a dramatic flair and superb defense in both right and center. But, by the second half, he could not catch up to elevated fastballs and hit just .211/.256/.370/.627 after the break. He struck out 194 times, third most in the majors.

Whats new for 22: Taveras posted an .818 OPS at Triple-A Round Rock and a .742 OPS in the Dominican Winter League, big steps up in terms of offensive production from his career minor league OPS of .701. If he takes another step forward, he could make the outfield picture much more intriguing. But, its probably not feasible for him to completely make that argument in spring training and starting him on the bench in the majors seems counterproductive.

By the numbers: Garcas defense should not be overlooked. He saved 16 runs, according to Fangraphs, while moving around the outfield. He ranked 11th among MLB outfielders in runs saved. His arm is tremendous as are his leaping skills. His routes can occasionally be awkward, but hes got the speed to recover.

On the farm: Will former first-rounder Bubba Thompson continue the improvement he showed at Double-A Frisco last year? Will intriguing 2020 second-rounder Evan Carter be able to stay healthy this year? Both are interesting stories in the minors for 2022, but Taveras is probably the only prospect who may figure into the picture in center in the majors this year.

What it means: The Rangers did major lifting on the infield in November, but not so much on the outfield. It remains in a very fluid state with the biggest certainty being Garca, who is entering his second MLB season at age 29 and looked overwhelmed often in the second half. A free agent outfielder capable of playing center or left could drastically change the dynamics. There is a need for more help.

Catcher | First base | Second base | Shortstop | Third base | Left field | More coming soon...

Find more Rangers coverage from The Dallas Morning News here.

View post:

Rangers 2022 positional analysis: CF Adolis Garca is the only certainty in an uncertain outfield - The Dallas Morning News

By Ben GrayPublished: February 16, 2022 5:33 pm

At the moment there is no player information for this match. Please check later.

The last 13 meetings of these two sides, dating back to 2009, have produced 38 goals.

Both teams to score is 1/1.

Lucas Boy has seven goals to his name this season, including two in his last three. He is 15/2 to break the deadlock and 3/1 to score anytime.

Advertisement

Will Rayo Vallecanos deteriorating form continue?

Last weekend, los Franjirrojos were hammered 3-0 by Osasuna at home, meaning theyve now taken just one point from five games in 2022.

On New Years Day, Andoni Iraolas side were, against all odds, fourth in the table but have now slid all the way down to 11th.

Also, nine days ago, they were beaten 2-1 at Campo de Ftbol de Vallecas by Real Betis in the Copa del Rey semi-final first leg.

For context, los Vallecanos had made a remarkable start as a newly-promoted club and are competing in their first major semi-final for four decades.

That said, they need to address their losing run.

Elche meanwhile are now just three places and five points below their visitors.

Los Franjiverdes began this year in fantastic form before their five-match unbeaten run came to an end last weekend.

In that one, Franciscos side were beaten 2-0 by Sevilla with both goals at Estadio Ramn Snchez Pizjun coming just five minutes apart.

Nevertheless, Elche kick off six points clear of danger and theyll be more than happy with that.

Will there be a winner at Estadio Manuel Martnez Valero?

Top scorer Lucas Boy actually missed the defeat at Sevilla last weekend so Francisco will be desperately hoping has back and available for this one.

Guido Carrillo would therefore be back on the bench with Pere Milla Boys usual partner.

Andoni Iraola might be tempted to make changes to his XI given the poor run of form theyre on.

36 year old Radamel Falcao will continue to lead the line, looking to add to his first goals for the club.

Stole Dimitrievski missed the first four La Liga games of 2022 out injured, with Luca Zidane deputising in goal, but the North Macedonian is fit now.

Elche CF vs Rayo Vallecano form

Sevilla FC vs Elche CF - 2:0

Elche CF vs Deportivo Alaves - 3:1

Real Madrid vs Elche CF - 2:2

Elche CF vs Real Madrid - 1:2

Elche CF vs Villarreal CF - 1:0

Rayo Vallecano vs CA Osasuna - 0:3

Rayo Vallecano vs Real Betis Seville - 1:2

RC Celta de Vigo vs Rayo Vallecano - 2:0

Rayo Vallecano vs RCD Mallorca - 1:0

Rayo Vallecano vs Athletic Bilbao - 0:1

Last 5 games for Elche CF

Last 5 games for Rayo Vallecano

Elche CF vs Rayo Vallecano LaLiga 21/22 form

Elche CF vs Rayo Vallecano statistics for most recent head tohead matches

Last 5 games & match results between Elche CF and Rayo Vallecano

101 Great Goals may earn commission from links on this page. Our content is always original. Note that all of our reviewers are compensated for contributing content to 101 Great Goals. Learn more.

Visit link:

Elche vs Rayo Vallecano betting tips: La Liga preview, predictions and odds - 101 Great Goals

[110 Pages Report] CF & CFRP Market Insights 2022 This report contains market size and forecasts of CF & CFRP in United States, including the following market information:

United States CF & CFRP Market Revenue, 2016-2021, 2022-2027, (USD millions)

United States CF & CFRP Market Sales, 2016-2021, 2022-2027, (K MT)

United States top five CF & CFRP companies in 2020 (%)

The global CF & CFRP market size is expected to growth from USD 23060 million in 2020 to USD 35640 million by 2027; it is expected to grow at a CAGR of 6.0% during 2021-2027.

The United States CF & CFRP market was valued at USD million in 2020 and is projected to reach USD million by 2027, at a CAGR of % during the forecast period.

The Research has surveyed the CF & CFRP manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19499157

Leading key players of CF & CFRP Market are

CF & CFRP Market Type Segment Analysis (Market size available for years 2022-2027, Consumption Volume, Average Price, Revenue, Market Share and Trend 2015-2027): Polyacrylonitrile Carbon Fiber, Pitch Based Carbon Fiber, Rayon Carbon Fiber, Thermosetting CFRP

Regions that are expected to dominate the CF & CFRP market are North America, Europe, Asia-Pacific, South America, Middle East and Africa and others

If you have any question on this report or if you are looking for any specific Segment, Application, Region or any other custom requirements, then Connect with an expert for customization of Report.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/19499157

For More Related Reports Click Here :

Vacuum Hardening Furnaces Market In 2022

Specialty Graphite Market In 2022

Go here to see the original:

(New Report) CF & CFRP Market In 2022 : The Increasing use in Aerospace, Automotive, Ship, Medical is driving the growth of the Industry across...

A team of scientists in New York has created small molecules called antisense oligonucleotides that could be used to skip over the mutated part of theCFTR gene to treatcystic fibrosis (CF) patients with a specific nonsense mutation and no available therapies.

Findings were published in the study, Exon-skipping antisense oligonucleotides for cystic fibrosis therapy, published in the journalPNAS.

CF is caused by mutations in theCFTR gene, which provides instructions for making the CFTR protein. This protein is important for regulating the movement of water and salts in and out of cells.

In recent years, a class of medications called CFTR modulators such as the triple-combo therapy Trikafta, by Vertex Pharmaceuticals has become widely available to treat CF. These medicines can increase the activity of the CFTR protein, but they only work in people with certain disease-causing mutations.

Many mutations in the CFTR gene are not responsive to drugs used to treat CF, Young Jin Kim, a doctoral student at Stony Brook University and the studys first author, said in a press release.

In particular, CFTR modulators do not work as treatments of nonsense mutations. A nonsense mutation is a change in the genetic code that results in a stop signal halfway through a gene kind of like putting a period in the middle of a sentence.

There is a significant unmet therapeutic need for patients with this type of mutation, Kim said.

A nonsense mutation called W1282X is the sixth most common CF-causing mutation. Its present in about 1.2% of patients and tends to be associated with more severe disease.

Within a cells DNA, genes are divided into sections called exons. When a gene gets read, all the exons are strung together in the messenger RNA (mRNA) sent to the cells protein-making machinery (ribosomes).

The W1282X mutation is located in exon 23 of theCFTRgene. Here, researchers tested if skipping over this exon might allow cells to produce a shorter, but still functional, version of the CFTR protein. Similar approaches have been successfully developed to treat disorders such as Duchenne muscular dystrophy.

In initial proof-of-concept experiments, the researchers illustrated that a shortened CFTR protein, made without exon 23, is biologically active. Based on measures of salt movement in and out of cells, the shortened protein was roughly half as active as the unmutated protein when treated with Trikafta.

As low as 10% of normal CFTR function would provide a significant therapeutic benefit for CF patients who have a near-complete loss of CFTR function, as is the case for the W1282X mutation, the scientists wrote, noting their findings support this overall treatment approach.

Researchers then designed antisense oligonucleotides, or ASOs, which are basically short pieces of genetic code that can modulate the genetic activity of the cell. Two ASOs that could promote skipping of exon 23 were identified

The team showed that treatment with the two ASOs, plus the two CFTR modulators present in Orkambi (ivacaftor/lumacaftor), could increase CFTR activity in cells carrying the W1282X mutation. (Orkambi is approved to treat patients with the common F508del mutationin bothCFTR gene copies.)

CFTR activity in these treated cells is likely less than 10% what it is in cells with no mutation, the scientists said. We anticipate that combining the ASO cocktail with Trikafta may further increase the CFTR activity, they wrote.

These researchers are now hoping to progress their approach toward clinical trials.

Our results thus provide an avenue for developing a therapeutic strategy based on [exon-skipping] ASO, in the era of CFTR-modulator therapy, they concluded.

Read this article:

For CF Nonsense Mutations, Exon-Skipping May Be Promising Approach - Cystic Fibrosis News Today

Current treatments for cystic fibrosis are not suitable for all patients. The lack of treatment options is distressing for people suffering from a rare type of this degenerative and life-threatening disease. But researchers are making major advances.

A decade ago, few cystic fibrosis patients lived beyond their teens. Thanks to a breakthrough in treatment options, for most patients with access to modern medicines, cystic fibrosis (CF) is no longer the catastrophic disease it once was. However, for 15% of people with CF, the cellular defect that causes their disease remains untreatable. For these patients, drugs are available to treat some of the symptoms of CF, but the condition continues to wreak havoc with their organs, resulting in premature death.

An EU-funded research projectHIT-CFaims to change this by improving both the quality of life and the disease prognosis for people with ultra-rare varieties of CF. In Europe, there are an estimated 5,250 people who fall into this category.

The project, launched in January 2018, brings together researchers, doctors, pharmaceutical companies and patient representatives, with the aim of developing drugs and drug combinations that are matched with a high degree of precision to a patient, regardless of the rarity of their form of the disease. Such personalised medicine is possible thanks to a new approach to drug testing involving the creation of mini-organs in the lab using a patients own stem cells. These organoids are genetic replicas of organs found inside the patients body and can be used to test how responsive a persons cells are to specific pharmaceutical compounds.

Were effectively shifting therapeutic trials from patients to the laboratory, explained Kors van der Ent, professor in paediatric pulmonology at the University Medical Centre, Utrecht in the Netherlands, and coordinator of the multi-disciplinary HIT-CF project.

To date, scientists involved in the project have grown organoids from 500 European patients with ultra-rare forms of CF. Ultra-rare can mean that just one or two people worldwide share the same form of the disease.

Describing his teams work with organoids, Professor van der Ent said: Weve asked pharmaceutical companies to hand over drugs from their development pipelines so we can test these compounds against the organoids. These drug candidates target the basic protein defect involved in cystic fibrosis.

What is special about this work is that it means we can create highly personalised treatments for patients with rare mutations. Whats also special is that we can mix and match compounds from different companies to see if patients are responsive to a certain combination of drugs.

From April, the projects clinicians will start testing compounds that have proven to be effective on organoids on real-life patients. We expect these patients to respond well, said Professor van der Ent. We hope that within five years, these patients will have new drugs.

Targeting the cystic fibrosis gene

One in 35 people carries the faulty gene that causes CF usually without knowing. Two people carrying the faulty gene have a 25% chance of having a child born with the disease. Without modern treatment, most people born with CF do not live long beyond their thirties.

Until recently, the only way to treat CF was with antibiotics to fight infection, steroids to reduce inflammation, physiotherapy to clear airways, exercise, nutrition and transplants (of the lungs, liver and sometimes other organs). Although the disease still remains incurable, since 2012, a new class of drugs called modulators has transformed treatment for many.

CFTR modulators target specific defects in the CFTR protein, thereby restoring healthy function of the protein so that chloride (which is present in salt) can flow across the cell surface. To date,four such modulators have reached the market, and these drugs are both transforming the quality of patients lives and lengthening their lifespan substantially.

Thanks to these drugs, in some patients theres a lung-function improvement of 30-40% and life expectancy can increase from the age of 30-40 to 60-80, said Professor van der Ent. In other words, there can be a normal life expectancy.

One significant downside of CFTR modulators is their price: treatment costs up to 200,000 per patient per year. As a result, only patients in countries with a well-funded health service can access medication. Meanwhile, many patients in Eastern Europe, along with other less developed parts of the world, are missing out.

Another drawback and one that HIT-CF aims to address is that CFTR modulators are only being clinically tested in patients with well-described, common mutations of CF. There are up to 2,000 genetic mutations that lead to CF, but just 120 of these are responsible for 80-85% of disease occurrence. It is patients with these common forms of the condition who are able to benefit from the CFTR modulators currently on the market.

So why are patients with rare mutations being left behind? The high cost of clinical trials means it simply does not make commercial sense for drug companies to focus their efforts on this sub-group of CF patients.

Step in organoid technology

Scientists involved in the HIT-CF project are taking tissue samples from the rectum of patients with rare forms of CF, isolating stem cells, and growing these to form mini-intestines.

There are two major advantages of using organoids to screen potential drugs: there are no safety considerations for the patient, and the screening process is highly efficient (any number of compounds from a library of potential drug candidates can be thrown at an organoid, and at speed). As a result, the potential cost savings are vast. For participants of the HIT-CF project, this is great news.

This study is giving people who have been excluded from clinical studies the chance to be recruited for a study and to find medicines that will tackle the causes of their disease, said Dr Elise Lammertyn, head of research at the European federation of national CF patient organisationsCystic Fibrosis Europe, a partner in the HIT-CF project.

There are quite a few (conventional) clinical trials going on in Europe for cystic fibrosis, but most of these are only open to those with the most common mutations of the disease, and the 10-15% of people with ultra-rare mutations are left out in the cold. This new study is about personalised medicine at its most innovative.

Universal access to treatment

Prof. van der Ent, in partnership with other scientists involved in CF research, is set to launch Fair Therapeutics a company that will set out to use organoid technology to bring CF drugs to market for patients with both common and rare mutations, at affordable prices.

In a sense well be competitors to big pharma but actually we will all be working towards the same goal of reaching all CF patients, said Professor van der Ent.

First, however, the project scientists must acquire permission from the European Medicines Agency (EMA) to approve organoid testing so it can be used beyond the current study. It will be very helpful to have a test in the lab that can be used in conjunctionwith less lengthy clinical trials to prove the effectiveness of drugs in small groups of people, said Professor van der Ent. It will highly speed up the pipeline of new drugs for all kinds of diseases, not just CF. It could even be used as a predictive tool for cancer treatment: you do a biopsy of a tumour, add chemotherapy and other drugs to the organoid, and then use the most sensitive treatment on the tumour.

The research in this article was funded by the EU. This article was originally published in Horizon, the EU Research and Innovation Magazine.

Related

Read more from the original source:

Currently theres no cure for rare types of cystic fibrosis, but researchers are making significant advances - Modern Diplomacy

Living up to his moniker The King Puncher with a career-defining 12 months, in which he claimed three noteworthy victories to inch him closer to a chance of vying for a World Title in the flyweight division,Ali Bagautinov was voted by fans as BRAVE CFs 2021 Fighter of The Year.

Even among the dominant World Champions, serial finishers, and other stars on the BRAVE CF roster, no one can quite match his run in 2021 as he won all of his bouts that included two wins in the prestigious BRAVE CF Flyweight Title Tournament to punch a ticket to the finals against the highly-touted Velimurad Alkhasov at a yet-to-be-announced event in 2022.

Bagautinov kicked off his 2021 by making his highly-anticipated promotional debut at BRAVE CF 46 this past January, dominating Oleg Lichkovakha throughout three rounds to clinch a clear-cut unanimous decision win and secure a slot in the BRAVE CF Flyweight World Title Tournament.

The Russian dynamo then picked up where he left off nearly three months later by eliminating fellow veteran Dustin Ortiz from the tourney in the same fashion at BRAVE CF 50.

At BRAVE CF 55, The King Puncher capped off his amazing run by stopping short-notice opponent Sean Santella in 61 seconds to set a date with Alkhasov for the inaugural BRAVE CF Flyweight World Championship.

Joining Bagautinov is Nursulton Ruziboev, who won the KO Of The Year award for a rare slam KO win reminiscent of Quinton Jackson vs Ricardo Arona, when he knocked out Ibrahim Mane at BRAVE CF 47.

Asu Almabaev, the Flyweight star from Kazakhstan, won two prizes sub of the year for his rear-naked choke finish of Aleksander Doskalchuk, and breakthrough fighter of the year.

Finally, a Super Welterweight war between Ismail Naurdiev and Olli Santalahti, at BRAVE CF 54, was voted Fight of The Year.

BRAVE CF 2021 Award Winners

Roberto Villa is the CEO, Founder, Executive Writer, Senior Editor of FightBook MMA. Has a passion for Combat Sports and also a podcast host for Sitting Ringside. Hes also a former MMA fighter and Kickboxer.

Like Loading...

----------------------------------------

#MMA #CombatSportsNews #BRAVECF #UFC #MuayThai #Boxing #Kickboxing #Prowrestling #BareKnuckleFighting

Read more:

Ali Bagautinov Clinches 2021 BRAVE CF Fighter Of The Year, rare slam gets KOTY award - FightBook MMA

Item 1.01 Entry into a Material Definitive Agreement.

On January 28, 2022, CF Industries Holdings, Inc. ("CF Industries") and CFIndustries, Inc. ("CFI") entered into supplements to the indentures governingCFI's 3.450% Senior Notes due 2023 (the "2023 Notes"), 4.500% Senior SecuredNotes due 2026 (the "2026 Notes"), 5.150% Senior Notes due 2034 (the "2034Notes") and 4.950% Senior Notes due 2043 (the "2043 Notes"), and on January 31,2022, CF Industries and CFI entered into a supplement to the indenture governingCFI's 5.375% Senior Notes due 2044 (the "2044 Notes," and the 2023 Notes, the2026 Notes, the 2034 Notes, the 2043 Notes and the 2044 Notes being referred toherein in each case as a "series of Notes" and collectively as the "Notes"),with Wells Fargo Bank, National Association ("Wells Fargo"), as trustee (and,with respect to the 2026 Notes, as collateral agent). The supplement in the caseof each series of Notes provided for amendments of the applicable indenture toremove CF Industries' United Kingdom subsidiaries from the definition ofSignificant Subsidiary (as defined in such indenture) and from being consideredto be part of a group of subsidiaries of CF Industries that would, takentogether, constitute a Significant Subsidiary of CF Industries. In the case ofeach series of Notes, CFI received consent to such amendments from holders of amajority of the outstanding aggregate principal amount of such series of Notes.The amendments in the case of each series of Notes became operative onFebruary 1, 2022, upon payment by CFI of a consent fee to the consenting holdersof such series of Notes.

The foregoing description of the indenture supplements is qualified in itsentirety by reference to the full text of the supplements with respect to the2023 Notes, the 2026 Notes, the 2034 Notes, the 2043 Notes and the 2044 Notes,which are attached hereto as Exhibits 4.1, 4.2, 4.3, 4.4 and 4.5, respectively,and incorporated herein by reference.

Wells Fargo is a lender under CFI's Revolving Credit Agreement (as definedbelow). Wells Fargo has advised CF Industries that Computershare Limited("Computershare") completed the acquisition of the assets of Wells FargoCorporate Trust Services on November 1, 2021, and that the trusteeships underthe indentures governing the Notes would transfer to an affiliate ofComputershare at a time to be determined. An affiliate of Computershare is thetransfer agent and registrar for CF Industries' common stock.

On January 27, 2022, CF Industries and CFI entered into that certain AmendmentNo. 1 to the Fourth Amended and Restated Credit Agreement, dated as of January27, 2022 (the "Credit Agreement Amendment"), with the lenders party thereto, theissuing banks party thereto and Citibank, N.A. ("Citibank") as administrativeagent. The Credit Agreement Amendment amended that certain Fourth Amended andRestated Credit Agreement, dated as of December 5, 2019 (as amended, restated,amended and restated, supplemented, waived or otherwise modified prior to thedate of the Credit Agreement Amendment, the "Existing Credit Agreement", theExisting Credit Agreement, as amended by the Credit Agreement Amendment, the"Revolving Credit Agreement"), among CF Industries, CFI, the lenders partythereto, the issuing banks party thereto and Citibank as administrative agent,to, among other things, exclude each of CF Industries' United Kingdomsubsidiaries and each of their subsidiaries from being a Material Subsidiary (asdefined in the Revolving Credit Agreement) of CF Industries under the RevolvingCredit Agreement. The Credit Agreement Amendment also (i) changed the thresholdabove which a subsidiary would constitute a Material Subsidiary from 5% of theconsolidated total assets of CF Industries and its subsidiaries to 10% ofconsolidated total assets of CF Industries and its subsidiaries and (ii)replaced the threshold above which a subsidiary would constitute a MaterialSubsidiary from 5% of consolidated gross sales of CF Industries and itssubsidiaries to 10% of consolidated EBITDA of CF Industries and itssubsidiaries. Furthermore, the Credit Agreement Amendment changed the referencerate for (i) borrowings under the Revolving Credit Agreement denominated inEuros from LIBOR to EURIBOR and (ii) borrowings under the Revolving CreditAgreement denominated in Sterling from LIBOR to SONIA.

The foregoing description of the Credit Agreement Amendment is qualified in itsentirety by reference to the full text of the Credit Agreement Amendment, whichis attached hereto as Exhibit 4.6 and incorporated herein by reference.

Each of the lenders and issuing banks party to the Revolving Credit Agreement,Citibank and certain of their respective affiliates have performed or may in thefuture perform various commercial banking, lending, investment banking,financial advisory, trustee, hedging or other services for CF Industries, CFIand subsidiaries and affiliates of CF Industries and CFI for which they havereceived or will receive fees and reimbursement of expenses.

Item 3.03 Material Modification to Rights of Security Holders.

The information in Item 1.01 of this report with respect to the 2023 Notes, the2034 Notes, the 2043 Notes and the 2044 Notes is incorporated by reference inthis Item 3.03.

Item 9.01 Financial Statements and Exhibits.

Exhibit No. Description of Exhibit

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded

Edgar Online, source Glimpses

Visit link:

CF INDUSTRIES HOLDINGS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements...

According to a Trends Market research report titledCarbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) MarketGlobal Industry Perspective, Comprehensive Analysis and Forecast by 2021 2030. The Research study on Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market is a crucial document for the industry players to understand competitive Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market scenario. The base year considered for Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market analysis is 2020. The report presents Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market industry chain structure, market overview, present industry statistics, market share & volume. All Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market industry is spanned across regions namely North America, Europe, Asia-Pacific, Middle East & Africa, South America and Rest. Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market key players analysis, regional analysis, product insights, Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market types, and applications are elaborated.

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Download Research Sample with Industry Insights @https://www.trendsmarketresearch.com/report/sample/6261

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, The Report has segmented global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market on the basis of types, technology and region

Various secondary sources, such as encyclopedia, directories, and databases to identify and collect information useful for this extensive commercial study of Global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market have been used. The primary sources, experts from related industries and suppliers, have been interviewed to obtain and verify critical information as well as to assess the future prospects of Global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market.

The Global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market Research Report is a comprehensive and informative study on the current state of the Global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market industry with emphasis on the global industry. The report presents key statistics on the market status of the global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Enquire for Discount Or Get Customization of Report @https://www.trendsmarketresearch.com/checkout/6261/Single

Regional Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market (Regional Output, Demand & Forecast by Countries):-North America (United States, Canada, Mexico)South America ( Brazil, Argentina, Ecuador, Chile)Asia Pacific (China, Japan, India, Korea)Europe (Germany, UK, France, Italy)Middle East Africa (Egypt, Turkey, Saudi Arabia, Iran) And More.

The research report studies the past, present, and future performance of the global market. The report further analyzes the present competitive scenario, prevalent business models, and the likely advancements in offerings by significant players in the coming years.

Main Highlights of Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market Report: The report offers an analytical study on various global Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market industries to provide decisive data. The top market segment analysis and market drivers are explained in this report. A mix of primary and secondary research methodology provides authentic and reliable data. A separate section is dedicated for competitive scenario and market statistics. The clear and concise study on Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market dynamics, cost structures will yield useful results. Latest developments and trends in Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market are evaluated in this report.

Get Up to 10 % Discount on single User @https://www.trendsmarketresearch.com/report/discount/6261

This study offers past, present and forecasts information on Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market. The data is represented in form of tables, infographics, charts to provide an easier view.

Read more:

Carbon Fiber and Carbon Fiber Reinforced Plastic (CF & CFRP) Market Overview with In-depth Analysis and Experts Review Report 2021-2030 ...

Turaathwas no match for Marabi in Saturdays Group 2 Australia Stakes (1200m), but her performance did little to dampen Maddie Raymonds enthusiasm for the campaign ahead.

The Warrnambool trainer reported on Sunday morning that the imported mare came through her third placing really well and it was full steam ahead to the Group 1 C.F. Orr Stakes at Caulfield on February 12.

Shes never won over 1200 metres in her life so to be there at weight-for-age level running third in a Group 2 over a distance that isnt her best, were pretty excited for the next couple of runs, Raymond said.

We said if we ran top three that we would be going to the Orr knowing over 1400 back at Caulfield she can be up on the speed and make her own luck.

That was going to be the target which we had her peaking for and knowing that shed need a couple of runs under her belt so were definitely on track and relatively confident.

The Australia Stakes followed a fifth placing in the Group 3 Standish Handicap on January 15, which have been her only two runs since completing a four-race winning streak in the Group 2 Lets Elope Stakes (1400m) on September 11.

The daughter of Oasis Dream was never a threat to Marabi, who was eased down to score by 2-3/4 lengths, but Raymond thought she could have held eventual second placegetter Sinawann with a smoother run in transit.

It got a little bit messy, we got knocked around a little bit and had to get going a bit sooner than what we expected but shes a really tough, honest mare, Raymond said of the five-year-old, who was ridden by Damian Lane.

We probably could have run second if we didnt have the interference, but we knew we were coming here today to run well with improvement in her next run.

Sinawann leapt to $4 joint favouritism with Im Thunderstruck in TABs Orr Stakes odds with Turaath occupying a place on the $15 line.

*Existing customers only. 2nd Racing bet. Excl SA & WA. Ts & Cs apply. Gamble responsibly.

See the article here:

Turaath ready to peak in the CF Orr Stakes - Just Horse Racing